Rendez-vous Samedi 18 octobre 2025 à partir de 12h00 – Hall 25 à l’ESMO ou dès lundi sur la page pour visualiser les posters

 

 

1899P: Predicting the efficacy of immunotherapy in advanced NSCLC: are clinical scores really useful ?

Julien Ancel, Olivier Bylicki, Jean Baptiste Assié, Chantal Decroisette, Renaud Descourt, Hubert Curcio, Charles Ricordel, Romain Corre, Laurent Greillier, and Nicolas Paleiron.

 

 

2027TiP: REPOROS trial-GFPC 04-2023: open-label phase II efficacystudy of repotrectinibin frail patients with ROS1-rearranged metastatic NSCLC

Laurent Greillier, Gaelle Rousseau Bussac, Thomas Pierret, Hélène Doubre, Margaux Geier, Yannick Simonneau , Lionel Falchero, Stéphanie Martinez, Florian Guisier, Yannick Le Guen, Grégoire Justeau, Laurence Bigay Game, Pierre Demontrond, Acya Bizieux, Julian Pinsolle, Maël Domblides, Claire Bardel, Lionel Moreau, Alexis Cortot, Olivier Bylicki.

 

 

2969P: Long-term real-life outcomes of nivolumab-ipilimumab combination in untreated patients with unresectable pleural mesothelioma. Update of MESOIMMUNE – GFPC 04 -2021 study 

Laurent Greillier, Florian Guisier, Arnaud Scherpereel, Catherine Daniel, Aurélie Swalduz, Emmanuel Grolleau, Marie Bernardi, Stéphane Hominal, Jean-Briac Prévost, Guillaume Pamart, Marie-Hélène.Marques, Nicolas Cloarec, Simon Deshayes, Judith Raimbourg, Rémi Veillon, Youssef Oulkhouir, Clarisse Audigier Valette, Florent Martin, Clothilde Deldycke, Olivier Bylicki, on behalf of GFPC. 

 

 

2007P – Tolerance and efficacy of targeted therapies after immunotherapy in metastatic non-small cell lung cancer with molecular alterations: TOXIMAD GFPC 04-2022 study

Thomas Pierret, Jean-Bernard Auliac, Charles Ricordel, Catherine Daniel, Jessica Nguyen, Florian Guisier, Aurélie Swalduz, Hubert Curcio, Anne-Laure Desage, Laurence Bigay Game, Eric Huchot, Lionel Falchero, Hélène Doubre, Olivier Bylicki, Christos Chouaid, Laurent Greillier